How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

Strategies for Developing Potency Assays for Optogenetic Gene Therapy in Retinal Diseases

Introduction

The development of optogenetics-based gene therapies for inherited retinal diseases represents a transformative strategy for vision restoration but presents unique challenges in pharmaceutical development. One of the most critical and technically complex hurdles is establishing robust, regulatory-compliant potency assays. Unlike conventional biologics, for which potency is often defined by a single quantitative bioassay, optogenetic gene therapies require evaluation of a cascade of interdependent biological events: viral vector delivery, transgene expression, light-sensitive protein (e.g., opsin) maturation and membrane localization, light-gated ion channel function, and the resulting electrophysiological response at the cellular level ⁽¹⁾. This essay explores the scientific rationale, assay design strategies, and emerging methodological solutions for developing potency assays specifically aligned with the unique mechanism of action of optogenetic therapeutics.

What is Optogenetic Gene Therapy?

Optogenetic gene therapy is an advanced therapeutic modality that combines gene therapy with optogenetics to enable precise, light-mediated control of cellular activity. This precision medicine approach offers reversible and programmable therapeutic effects, most notably for restoring vision in blindness. Optogenetic therapies encompasses a range of approaches that combine genetic engineering with optical physics to modulate cellular function through light-controlled activation of ion channels, intracellular signaling pathways, or gene expression. Applications span neuroscience ⁽²⁾, retinal gene therapy ⁽³⁾, and cardiac optogenetics ⁽⁴⁾, where light is used to precisely control cardiac electrical activity.

While traditional gene therapy typically works by replacing a defective gene to “fix” a cell, optogenetics instead “reprograms” a cell to become light-sensitive, effectively turning it into a biological switch or sensor. In optogenetic gene therapy, genes encoding light-sensitive proteins, such as opsins, are delivered, most commonly using adeno-associated virus (AAV) vectors, into target cells, including neurons or retinal cells. After expression, opsins localize to the cell membrane and convert specific wavelengths of light into electrical or biochemical signals, enabling light-controlled activation or inhibition of cell activity with millisecond precision.

The most clinically advanced application is in inherited retinal degenerative diseases, such as retinitis pigmentosa, where surviving retinal neurons are converted into artificial photoreceptors and activated using external light-delivery devices, resulting in partial restoration of vision. Beyond ophthalmology, optogenetic gene therapy is being explored preclinically for neurological and other excitable-tissue disorders, though challenges remain in light delivery, dose control, and regulatory development.

Why Optogenetic Gene Therapy Potency Assessment Requires a Specialized Approach

Optogenetic gene therapy products are best understood as function-enabling medicines, in which therapeutic activity depends not only on transgene expression but also on the efficient conversion of light into a biological signal within target cells. In retinal optogenetic programs, such as delivery of ChrimsonR ⁽⁵⁾, a red-shifted, light-activated opsin, to surviving retinal ganglion cells in combination with light-stimulating goggles, clinical efficacy relies on a coordinated sequence of events:

Successful vector delivery to the eye
Productive cellular transduction and transgene expression
Appropriate membrane localization of the opsin with sufficient chromophore availability
Generation of light-evoked signals capable of engaging downstream retinal circuitry

Clinical reports in retinitis pigmentosa have highlighted this integrated “gene-device-training” paradigm, emphasizing the importance of stable opsin expression and well-controlled light stimulation for achieving functional visual responses ⁽⁶⁾.

Regulatory Expectations Translated into Assay Strategy

Regulatory guidance from the FDA emphasizes that potency assays for gene therapy products must be product-specific and reflect the intended biological activity ⁽⁷⁾. In practice, sponsors commonly implement a tiered potency strategy that combines vector attribute assessments, expression-based readouts, and functional assays. Vector attributes such as genome titer and particle integrity provide important supporting information but are not sufficient alone to define potency. Expression-linked assays measuring transgene RNA or protein levels are often used due to their scalability and stability-indicating properties. However, functional assays that directly reflect the mechanism of action, such as light-evoked membrane depolarization or electrophysiological responses, provide the most meaningful assessment of optogenetic activity.

FDA CBER guidance further highlights the importance of establishing quantitative, mechanism-based potency assays that are qualified or validated in a phase-appropriate manner, particularly prior to pivotal clinical studies for AAV products ⁽⁸⁾. For optogenetic gene therapies, the most robust approach is typically a cell-based functional potency assay used for lot release, supported by orthogonal expression and vector characterization assays for comparability and investigation. These expectations are consistent across regulatory agencies, including the EMA, underscoring the need for potency assays that measure true optogenetic function rather than surrogate markers.

Potency Assay Design: The Mechanism-of-Action-to-Measurement Map

Potency assay design for optogenetic gene therapy begins with a clear mapping of the product’s mechanism of action (MOA) to measurable biological outputs, with careful distinction between critical quality attributes and supporting indicators. For opsin-based AAV products, this mechanism typically encompasses several sequential steps:

Efficient capsid-mediated transduction and nuclear delivery
Promoter-driven transgene expression
Functional competence of the opsin protein

Functional competence requires correct protein folding, chromophore binding, membrane localization, and wavelength-specific channel gating that produces a measurable depolarizing or electrophysiological response. At the system level, particularly in vivo, therapeutic activity further depends on sufficient numbers of responsive cells within the appropriate retinal layer and compatibility of opsin activation with the external light-delivery device.

Optogenetic-Specific Considerations

Potency assessment is uniquely influenced by optogenetic-specific risks, as light itself becomes a critical assay variable. Wavelength, intensity, pulse pattern, and exposure duration directly shape functional output. High levels of expression do not necessarily translate into potency if membrane trafficking or folding is compromised. Assay performance depends on controlled chromophore availability and biologically relevant cell models that support both AAV transduction and neuronal excitability. For retinal applications, the coupling between the gene therapy product and the light-stimulation device further necessitates careful selection of representative yet reproducible stimulation conditions.

An effective potency assay for optogenetic gene therapy must be:

Mechanism-of-action relevant
Quantitative across a usable dynamic range
Stable and precise for quality control use
Sensitive to meaningful changes arising from degradation, process variation, or formulation effects

Methods Toolbox for Optogenetic Gene Therapy Potency Testing

A. Expression-Linked Potency Assays

Expression-linked potency assays are often practical, particularly in early development, because they are generally more reproducible and easier to qualify than functional assays. These assays serve as valuable supporting indicators when appropriately correlated with functional activity.

RT-qPCR/RT-ddPCR for Transgene mRNA: Measurement of transgene mRNA by RT-qPCR or RT-ddPCR is widely used, with one-step RT-ddPCR approaches demonstrating value as potency-linked readouts for AAV products. The absolute quantification provided by ddPCR and its reduced dependence on standard curves can improve comparability across runs and development stages. For optogenetic gene therapy, such assays must be shown to correlate with functional activity, be sensitive to degradation or stress, and be performed in cell systems with controlled permissiveness and well-defined transduction conditions.

Protein Quantitation and Localization: Protein-based assays can provide additional support but must be interpreted cautiously, as total opsin expression may not reflect functional activity if membrane trafficking or folding is impaired. Protein assays are most informative when they assess cell-surface localization or other indicators of functional competence, using approaches such as non-permeabilized flow cytometry or imaging-based localization metrics. Fluorescent reporters illustrate how imaging tools can aid assessment of transduction and cell permissiveness without replacing functional potency assays.

Vector Attribute Assays: Vector attribute assays play an important supporting role in potency assurance but do not, by themselves, define biological potency. Measurements such as vector genome titer by qPCR or ddPCR, capsid content, particle integrity, and related characterization assays are essential for monitoring manufacturing consistency and for interpreting changes observed in functional potency. These assays are best positioned as supporting critical quality attributes, enabling meaningful comparability assessments following process changes, stability trending over the product lifecycle, and systematic root-cause investigations when functional potency drifts are detected.

B. Functional Cell-Based Potency Assays

Functional cell-based assays are preferred for late-stage release testing as they directly measure the intended biological activity of optogenetic products.

Fluorescence-Based Membrane Potential Assays: Fluorescence-based membrane potential assays represent a practical and scalable approach for functional potency assessment. A published conference poster describing development of a potency assay for the optogenetic AAV product GS030-DP (ChrimsonR-tdTomato delivered by an AAV2.7m8 vector) provides a representative example ⁽⁹⁾. In this assay, light-induced depolarization in transduced cells was quantified using a FLIPR® membrane potential dye under controlled illumination, enabling generation of dose–response curves and EC50-based potency metrics. Method development focused on optimizing cell line permissiveness, infection conditions, and incubation time, as well as controlling chromophore availability through inclusion of all-trans retinal. Assay performance characteristics such as Z’ factor and inter-day robustness were evaluated, aligning the method with quality control requirements. This approach is well suited for QC use because it directly measures the intended biological function of the opsin, is compatible with multiwell plate formats and automation, and yields quantitative potency outputs that support relative potency determination against a reference standard. Common sources of variability, including non-uniform light delivery, inconsistent retinal availability, and changes in cell health or confluency, can be mitigated through calibrated illumination systems, standardized retinal handling, and tightly controlled cell culture parameters.

Electrophysiology (Patch Clamp) and Multi-Electrode Array (MEA) Assays: Electrophysiological approaches, including patch clamp and MEA assays ⁽¹⁰⁾, provide the most direct measurement of light-gated currents and channel kinetics and are therefore valuable for mechanistic confirmation and assay characterization. However, due to their lower throughput and higher operator dependence, these methods are generally not practical as primary lot release assays and are better positioned as orthogonal tools to support assay development, comparability assessments, and investigation of potency drift.

Calcium Imaging: Calcium imaging can serve as an additional functional proxy in cell systems where opsin activation leads to voltage-gated calcium entry or downstream signaling ⁽¹¹⁾ . While useful in cases where membrane potential dyes perform poorly, calcium-based readouts require careful validation to ensure a clear and consistent linkage to opsin activity, as responses may be indirect or subject to pathway saturation.

An effective functional assay strategy typically prioritizes direct measurement of light-evoked membrane potential changes or currents as the primary potency readout, supported by electrophysiology or MEA as orthogonal confirmation methods and calcium imaging or ion flux assays as secondary proxies where appropriate.

C. Tailored Potency Assay Development Approaches

Based on the specific optogenetic modality, target cell population, and downstream signaling pathways involved, a range of tailored strategies can be adopted to develop robust cell-based potency assays.

Reporter Gene Assays: Reporter gene assays offer an indirect but sensitive means of assessing optogenetic activity by coupling light-induced opsin activation to downstream reporter expression, such as luminescent or fluorescent signals ^{(12, 13)}. These systems rely on activity-dependent promoters, including calcium-responsive elements, NFAT, or cAMP response elements, to amplify optogenetic signals and enable quantitative readouts. When adapted for AAV potency testing, reporter gene assays are typically implemented in two-component formats in which opsin-expressing vectors activate engineered reporter cells following light stimulation. This approach is well suited for automation and high-throughput workflows; however, it measures optogenetic function indirectly, introduces a temporal delay between activation and readout, and requires careful reporter design and validation.
Retinal Organoid–Based Assays: Retinal organoid, based assays provide a more physiologically relevant platform for optogenetic potency characterization by recapitulating key features of human retinal architecture, cellular diversity, and neuronal organization ⁽¹⁴⁾. In this setting, optogenetic AAV vectors can be evaluated using electrophysiological recordings, calcium imaging of light-evoked responses, and immunohistochemical analysis to assess transduction patterns and cell-type specificity. Although organoid-based systems offer valuable insight into mechanism of action and translational relevance, their technical complexity, variability,and limited throughput currently restrict their application to advanced characterization and bridging studies rather than routine lot release testing.

Phase-Appropriate Development of Potency Assays for Optogenetic Gene Therapies

A pragmatic approach to potency assay development recognizes that assay complexity should evolve in parallel with program maturation. Please read our white paper for more details: Selecting Bioanalytical Assays for FDA Approved Clinical Trials and Commercialization.

Early Development (Discovery Through IND-Enabling)

In early development, the primary objective is to establish proof of functional activity while maintaining speed and flexibility as understanding of the mechanism of action continues to develop. During this stage, gene expression assays such as RT-qPCR are often used as initial potency indicators, supported by protein expression measurements and simple functional readouts, including calcium imaging in permissive cell lines. Transient plasmid transfection systems are frequently employed to establish proof of opsin function prior to AAV vector optimization, allowing rapid iteration and selection of lead constructs.

Phase I/II Clinical Development

As programs advance into Phase I and II clinical development, the focus shifts toward quantitative assays that better correlate with anticipated clinical activity. Expression assays and flow cytometry methods are typically standardized, and functional assays such as electrophysiology or calcium imaging are qualified for their intended use. These assays begin to be correlated with emerging in vivo efficacy data to support dose selection and clinical interpretation. Regulatory guidance emphasizes that early demonstration of potential clinical benefit is important for gene therapy trials, and the use of multiple exploratory and functional endpoints in early-phase studies helps inform further assay refinement and development.

Phase III and Commercial

In Phase III and commercial stages, potency testing must support routine lot release and long-term product control, necessitating fully validated, GMP-compliant assays. A matrix-based strategy is commonly adopted, anchored by a primary functional potency assay that directly reflects the optogenetic mechanism of action, such as electrophysiology or a well-characterized calcium imaging assay, and supported by validated expression and protein localization methods. Potency specifications are established based on clinical lot experience, and validation is conducted in accordance with ICH Q2 expectations, including demonstration of specificity, linearity, range, accuracy, precision, and robustness.

Correlation and Bridging Strategies

Across all stages, establishing meaningful correlations between assays is a critical element of potency strategy. Correlation and bridging studies are used to:

Link expression-based measurements to functional activity
Relate in vitro potency to in vivo efficacy
Compare different functional readouts
Demonstrate that stability-indicating assays appropriately reflect changes in functional potency

This phased and integrated approach enables development of a potency control strategy that is scientifically grounded, regulatory-aligned, and adaptable as optogenetic gene therapy programs progress toward commercialization.

Conclusion

A mature and regulatory-aligned potency strategy for optogenetic gene therapy integrates multiple complementary assays to ensure consistent measurement of true biological activity. At its core, such a strategy is anchored by a primary, cell-based functional potency assay suitable for lot release, in which light-evoked membrane depolarization or current is quantitatively measured relative to a reference standard, with defined system suitability criteria such as plate acceptance metrics.

Orthogonal expression assays, including RT-qPCR or RT-ddPCR for transgene mRNA, provide important mechanistic support and enable investigation of potency shifts without supplanting functional readouts. These assays are complemented by a vector attribute panel assessing genome titer, integrity, and particle characteristics to support comparability and root-cause analysis.

Together with a robust system suitability and trending program incorporating reference standards, control charts, and predefined alert limits, this integrated framework provides a scientifically sound and operationally practical foundation for potency assurance as optogenetic gene therapies advance toward late-stage development and commercialization.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.